159 related articles for article (PubMed ID: 27766897)
1. Diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives act as acid phosphatase inhibitors: synthesis accompanied by experimental and molecular modeling assessments.
Alimoradi N; Ashrafi-Kooshk MR; Shahlaei M; Maghsoudi S; Adibi H; McGeary RP; Khodarahmi R
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):20-28. PubMed ID: 27766897
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase.
Mohd-Pahmi SH; Hussein WM; Schenk G; McGeary RP
Bioorg Med Chem Lett; 2011 May; 21(10):3092-4. PubMed ID: 21459576
[TBL] [Abstract][Full Text] [Related]
3. Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics.
Hussein WM; Feder D; Schenk G; Guddat LW; McGeary RP
Eur J Med Chem; 2018 Sep; 157():462-479. PubMed ID: 30107365
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis.
Feder D; Kan MW; Hussein WM; Guddat LW; Schenk G; McGeary RP
Eur J Med Chem; 2019 Nov; 182():111611. PubMed ID: 31445230
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of purple acid phosphatase with alpha-alkoxynaphthylmethylphosphonic acids.
McGeary RP; Vella P; Mak JY; Guddat LW; Schenk G
Bioorg Med Chem Lett; 2009 Jan; 19(1):163-6. PubMed ID: 19010677
[TBL] [Abstract][Full Text] [Related]
6. Identification of purple acid phosphatase inhibitors by fragment-based screening: promising new leads for osteoporosis therapeutics.
Feder D; Hussein WM; Clayton DJ; Kan MW; Schenk G; McGeary RP; Guddat LW
Chem Biol Drug Des; 2012 Nov; 80(5):665-74. PubMed ID: 22943065
[TBL] [Abstract][Full Text] [Related]
7. Penicillin inhibitors of purple acid phosphatase.
Faridoon ; Hussein WM; Ul Islam N; Guddat LW; Schenk G; McGeary RP
Bioorg Med Chem Lett; 2012 Apr; 22(7):2555-9. PubMed ID: 22366658
[TBL] [Abstract][Full Text] [Related]
8. Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases.
Valizadeh M; Schenk G; Nash K; Oddie GW; Guddat LW; Hume DA; de Jersey J; Burke TR; Hamilton S
Arch Biochem Biophys; 2004 Apr; 424(2):154-62. PubMed ID: 15047187
[TBL] [Abstract][Full Text] [Related]
9. Structural exploration of cinnamate-based phosphonic acids as inhibitors of bacterial ureases.
Ntatsopoulos V; Macegoniuk K; Mucha A; Vassiliou S; Berlicki Ł
Eur J Med Chem; 2018 Nov; 159():307-316. PubMed ID: 30300843
[TBL] [Abstract][Full Text] [Related]
10. Optimization of an α-aminonaphthylmethylphosphonic acid inhibitor of purple acid phosphatase using rational structure-based design approaches.
Feder D; Mohd-Pahmi SH; Adibi H; Guddat LW; Schenk G; McGeary RP; Hussein WM
Eur J Med Chem; 2023 Jun; 254():115383. PubMed ID: 37087894
[TBL] [Abstract][Full Text] [Related]
11. Rational design of some substituted phenyl azanediyl (bis) methylene phosphonic acid derivatives as potential anticancer agents and imaging probes: Computational inputs, chemical synthesis, radiolabeling, biodistribution and gamma scintigraphy.
Khedr MA; Rashed HM; Farag H; Sakr TM
Bioorg Chem; 2019 Nov; 92():103282. PubMed ID: 31541801
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the synthesis of 4'-truncated nucleoside phosphonic acid analogues.
Shen GH; Hong JH
Carbohydr Res; 2022 Mar; 513():108517. PubMed ID: 35152128
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of Potent Inhibitors of a Metallohydrolase Using a Fragment-Based Approach.
Feder D; Mohd-Pahmi SH; Hussein WM; Guddat LW; McGeary RP; Schenk G
ChemMedChem; 2021 Nov; 16(21):3342-3359. PubMed ID: 34331400
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human thymidine phosphorylase by conformationally constrained pyrimidine nucleoside phosphonic acids and their "open-structure" isosteres.
Košiová I; Šimák O; Panova N; Buděšínský M; Petrová M; Rejman D; Liboska R; Páv O; Rosenberg I
Eur J Med Chem; 2014 Mar; 74():145-68. PubMed ID: 24462848
[TBL] [Abstract][Full Text] [Related]
15. Phosphonate derivatives of tetraazamacrocycles as new inhibitors of protein tyrosine phosphatases.
Kobzar OL; Shevchuk MV; Lyashenko AN; Tanchuk VY; Romanenko VD; Kobelev SM; Averin AD; Beletskaya IP; Vovk AI; Kukhar VP
Org Biomol Chem; 2015 Jul; 13(27):7437-44. PubMed ID: 26058329
[TBL] [Abstract][Full Text] [Related]
16. 1-Aminobenzocyclobutene-1-phosphonic Acid and Related Compounds as Inhibitors of Phenylalanine Ammonia-Lyase.
Zoń J; Miziak P
Chem Biodivers; 2017 May; 14(5):. PubMed ID: 28171693
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Inhibitory Studies of Phosphonic Acid Analogues of Homophenylalanine and Phenylalanine towards Alanyl Aminopeptidases.
Wanat W; Talma M; Dziuk B; Kafarski P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32938014
[TBL] [Abstract][Full Text] [Related]
18. The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
McGeary RP; Schenk G; Guddat LW
Eur J Med Chem; 2014 Apr; 76():132-44. PubMed ID: 24583353
[TBL] [Abstract][Full Text] [Related]
19. Identification and molecular modeling of a novel, plant-like, human purple acid phosphatase.
Flanagan JU; Cassady AI; Schenk G; Guddat LW; Hume DA
Gene; 2006 Aug; 377():12-20. PubMed ID: 16793224
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of phosphonic arginine mimetics as inhibitors of the M1 and M17 aminopeptidases from Plasmodium falciparum.
Kannan Sivaraman K; Paiardini A; Sieńczyk M; Ruggeri C; Oellig CA; Dalton JP; Scammells PJ; Drag M; McGowan S
J Med Chem; 2013 Jun; 56(12):5213-7. PubMed ID: 23713488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
